Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 05, 2025
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: July 23, 2025
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants.
Journal: Annals of clinical and translational neurology
Published: January 17, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.
Journal: European journal of neurology
Published: May 02, 2024
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 22, 2023
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.
Journal: Annals of clinical and translational neurology
Published: April 06, 2023
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 29, 2022
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
Journal: European journal of neurology
Published: March 08, 2021
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
Journal: Multiple sclerosis and related disorders
Published: November 23, 2020
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
Journal: Multiple sclerosis and related disorders
Published: August 05, 2020
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: January 18, 2020
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Journal: The Lancet. Neurology
Published: February 15, 2019
Last Updated: 09/26/2026